SCHEMBL31467828

SCHEMBL31467828

CC(C)(C)OC(=O)c1ccc(N2CCC(CO)CC2)c(F)c1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.52
HPGD P15428 5/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
MAPT P10636 8/20 0.47
ALDH1A1 P00352 6/20 0.46
TSHR P16473 2/20 0.46
RAB9A P51151 3/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
NPC1 O15118 4/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
NPSR1 Q6W5P4 2/20 0.44
USP30 Q70CQ3 1/20 0.43
LMNA P02545 2/20 0.43
POLB P06746 1/20 0.42
ALOX15 P16050 1/20 0.42
MAPK1 P28482 1/20 0.42
HSD17B10 Q99714 1/20 0.42
HTR7 P34969 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22661325 1.00 GAA (0.52) GAAHPGDSMN1; SMN2MAPTALDH1A1
SCHEMBL25141493 0.88 MAPT (0.54) GAAHPGDSMN1; SMN2MAPTALDH1A1
SCHEMBL31467934 0.86 L3MBTL1 (0.56) GAAHPGDSMN1; SMN2MAPTALDH1A1
SCHEMBL31467820 0.83 GAA (0.49) GAAHPGDSMN1; SMN2MAPTALDH1A1
SCHEMBL22645558 0.83 GAA (0.49) GAAHPGDSMN1; SMN2MAPTALDH1A1
SCHEMBL25141633 0.82 GAA (0.55) GAAHPGDSMN1; SMN2MAPTALDH1A1
SCHEMBL1665672 0.82 MAPT (0.53) GAAHPGDSMN1; SMN2MAPTALDH1A1
SCHEMBL20046615 0.81 GPR119 (0.52) SMN1; SMN2MAPTALDH1A1MEN1KMT2A
SCHEMBL31467911 0.81 MAPT (0.49) GAAHPGDSMN1; SMN2MAPTALDH1A1
SCHEMBL31467835 0.81 MAPT (0.49) GAAHPGDSMN1; SMN2MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12577231-B2 Androgen receptor PROTACS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2026-03-17 US disclosed
US-20260001865-A1 ANDROGEN RECEPTOR PROTACS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2026-01-01 US disclosed
WO-2025061906-A1 ANDROGEN RECEPTOR PROTACS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2025-03-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260001865-A1 ANDROGEN RECEPTOR PROTACS AR, CRBN, PSMA3 GAA 4427/4885HPGD 3934/4885SMN1; SMN2 4159/4885
US-12577231-B2 Androgen receptor PROTACS AR, CRBN, PSMA3 GAA 4427/4885HPGD 3934/4885SMN1; SMN2 4159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.